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INTERVENCIÓN NUTRICIONAL EN EL
PACIENTE ONCOHEMATOLÓGICO
Resumen
Objetivos: Las enfermedades oncohematológicas como
el Linfoma o la Leucemia afectan a un número impor-
tante y creciente de personas en España. Tanto la enfer-
medad como las distintas modalidades de tratamiento
que puede llegar a precisar el paciente a lo largo del curso
de la misma impactan negativamente en el estado nutri-
cional del paciente, no siendo infrecuente el desarrollo de
desnutrición, situación que compromete la evolución, la
respuesta al tratamiento y la calidad de vida del paciente.
Método: La implementación de una estrategia multi-
disciplinar, sistematizada y protocolizada de valoración
nutricional puede resultar de utilidad a la hora de abor-
dar a los pacientes con enfermedades oncohematológicas.
Resultados: Se presenta una propuesta de protocolo de
evaluación y soporte nutricional en el paciente oncohema-
tológico elaborada a partir del análisis de la literatura
publicada al respecto, así como de la práctica clínica habi-
tual de un equipo sanitario multidisciplinar especial-
mente implicado en el manejo de los pacientes con enfer-
medades oncohematológicas.
(Nutr Hosp. 2012;27:669-680)
DOI:10.3305/nh.2012.27.3.5863
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Abstract
Background: Oncohematological diseases such as
lymphoma or leukaemia affect an increasing number of
newly diagnosed patients in Spain and other countries.
Both disease and treatment may have a negatively impact
in the nutritional status of the patient. Malnutrition is not
uncommon among oncohematological patients. This
situation can compromised the course of the disease, the
clinical response of the treatment and the patient’s
quality of life.
Method: The implementation of a multidisciplinary
approach and a systematic and protocolled nutritional
assessment would be useful when dealing with haematolo-
gical malignancies.
Results: We present a proposal of protocol for nutri-
tional intervention in oncohematological patients. This
proposal is been developed from the analysis of the
published literature as well as clinical practice of a multi-
disciplinary team specialized in the management of
patients with haematological malignancies. 
(Nutr Hosp. 2012;27:669-680)
DOI:10.3305/nh.2012.27.3.5863
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Introduction 
Neoplastic haematological diseases affect the blood,
bone marrow and lymphatic system. Of all onco-
haematological diseases, lymphomas represent a type
of cancer that has increased the most in Spain in recent
years, affecting more than one million people world-
wide. Non-Hodgkin’s lymphoma is the third fastest-
growing type of cancer. The incidence of lymphoma
increases by 3% per year, with the disease now repre-
senting the fifth leading cause of death from cancer.
According to the U.S. National Institutes of Health,
lymphomas account for 5% of all types of cancers in
the United States, with Hodgkin’s lymphoma accoun-
ting for only 1%. In Spain, it is estimated that the mean
incidence of lymphoma is 3 new cases per 100,000
inhabitants each year. Leukaemia is the most common
type of childhood cancer. More specifically, acute
lymphoblastic leukaemia (ALL) represents around
30% of all neoplasms, with 3-4 cases per 100,000 chil-
dren under age 15 per year. Acute myeloid leukaemia
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(AML) is a disease affecting adults, with a mean age at
diagnosis of 65 years, although it can occasionally be
seen in children. This type of leukaemia represents
40% of all cases of leukaemia in the Western world. Its
estimated incidence is 15 new cases per million inhabi-
tants each year. 
Malnutrition is common in cancer patients and has a
negative impact on disease outcome. However, its
prevalence in the specific case of onco-haematological
patients has not been well established. Some studies
show 27% malnutrition or nutritional risk in patients
undergoing haematopoietic stem cell transplantation
(HSCT).1
Malnutrition can cause a substantial increase in
morbidity and mortality in patients with onco-
haematological disease. One contributing factor is
the intensity of the treatment administered, inclu-
ding, in some cases, complex procedures such as
HSCT, which entails increased metabolic stress. In
addition, the side effects of treatment can lead to
some degree of patient malnutrition, especially side
effects relating to the gastrointestinal tract, which
may reduce and/or make intake, digestion and
nutrient absorption difficult. In addition to the anti-
neoplastic therapy, the disease itself contributes to
the state of protein-calorie malnutrition, leading to
reduced quality of life, increased complications and
decreased survival. This shows the need for a syste-
matic strategy to assess nutritional status that allows
adequate nutritional recommendations to be esta-
blished for each type of onco-haematological patient
based on clinical chemistry and anthropometric para-
meters, quantification of oral intake and tolerance,
and treatment- and disease-associated complications
that have an impact on nutritional status during
disease progression.2,3,4
The objectives of nutritional support in onco-haema-
tological patients include: maintaining good nutritional
status, preventing and/or treating complications asso-
ciated with the drugs used or the disease itself that have
an impact on nutritional support, and finally, improved
quality of life for the patient. It can therefore be
deduced that planning the right nutritional support for
each stage of the disease has enormous benefits for
patients. 
Malnutrition in onco-haematological patients
Although the haematological neoplasm itself may
cause increased metabolic stress and malnutrition, it is
actually the treatments that the patient will need that
are responsible for most of the mechanical or func-
tional alterations that may affect the digestive tract and
which will, in the end, have a negative impact on the
patient’s nutritional status (table I). The nutritional
status will be even more severely affected if the
neoplasm is more resistant to chemotherapy, some-
times requiring combinations of highly effective but
also highly toxic treatments. The different cytotoxic
agents, radiotherapy and other new drugs used in onco-
haematological treatment affect not only the tumour
cells but also healthy cells, especially those with a high
replication rate, as is the case of lymphocytes and
gastrointestinal tract cells (enterocytes, colonocytes).
The effects on these cells result in major functional
alterations of the digestive tract and immune system,
leading to malabsorption which seriously compro-
mises the patient’s nutritional status.
Malnutrition in onco-haematological patients is
often of the calorie-protein form. Malnutrition in these
patients has a major impact as it may worsen or prolong
the neoplastic treatment-induced immunosuppression,
increasing the risk of infectious complications, the
main cause of morbidity and mortality during acute
neoplasm treatment.5
There are other inherent causes of malnutrition,
such as the patients’ own acquired habits or previous
nutritional status (anorexia/cachexia not related to
the neoplastic disease), and it is therefore essential to
perform an initial nutritional assessment of the
patient and to apply the most suitable, protocol-
controlled and personalised nutritional support
possible in each case. 
Baseline nutritional status is a primary prognostic
factor and we should therefore indicate early nutri-
tional support in malnourished patients. 
In patients who are to undergo HSCT, the chemothe-
rapy/radiotherapy conditioning regimen used, haema-
topoietic stem cell source and possible complications
appearing during treatment (sepsis, graft-versus-host
disease, mucositis, etc.) will determine the increase in
nutritional requirements (which are generally hard to
meet), increased intestinal losses and a series of cata-
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Table I
The chemotherapy agents most commonly used
to treat onco-haematological diseases and associated
side effects
Alkylating agents Anti-metabolites Taxanes
Busulfan Paclitaxel
Cyclophosphamide Hidroxycarbamide
Procarbazine Methotrexate*
Thiotepa Mercaptopurine 
Melphalan Tioguanine
Vinca alkaloids Anti-tumour antibiotics
Vinblastine* Amsacrine
Vincristine Bleomycin 
Vinorelbine 
Anthracyclines Others
Daunorubicin Etoposide*
Doxorubicin* Teniposide
Epirubicin 
Idarubicin
*Cytostatic agents that commonly cause mucositis.
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bolic effects in skeletal muscle with unfavourable
consequences. As a result, a catabolic state tends to be
observed in these patients, which compromises both
protein and energy balance and micronutrient metabo-
lism. This balance will often be negative due to the
reduced intake associated with gastrointestinal symp-
toms that will make it hard to meet nutrient require-
ments.
Nutritional status assessment 
in onco-haematological patients
The primary objective of the nutritional status
assessment is to identify patients with or at risk of
malnutrition, either as a result of the disease itself or
the required treatments. The nutritional assessment
therefore makes it possible to detect those patients
requiring nutritional support and adequate monitoring
of such support.
Malnutrition causes changes in body composition,
including loss of body fat and fat-free mass, which
result in weight loss and alterations in other anthropo-
metric parameters and/or reduced plasma proteins.6
For the nutritional assessment, we will consider:
• Anthropometric data: Weight, height and body
mass index (BMI = Weight (kg)/Height2 (m)). The
patient’s prior BMI has prognostic implications for
patients who are to undergo HSCT, prolonging the
time to engraftment in patients with a BMI < 18.5.7
Weight loss over time must also be assessed. Unin-
tentional weight loss of more than 5-10% has a major
prognostic significance in cancer, especially if occu-
rring over a very short period of time of just weeks or a
few months.8,9 Weight loss of more than 10% in the 6
months prior to HSCT has a negative impact on the
transplantation outcome.
• Clinical chemistry parameters: Albumin must be
evaluated before starting onco-haematological treat-
ment. Figures below 2.5 g/dl suggest a high risk of
complications. Once treatment has started, its beha-
viour as an acute phase reactant and its long half-life
(21 days) make use as a nutritional marker difficult.
Albumin must be evaluated together with inflamma-
tory parameters such as C-reactive protein (CRP).
Elevated CRP levels may indicate a metabolic stress
situation that results in a low plasma albumin level
without showing the decrease in total body protein
reserve. 
Prealbumin10 has a shorter half-life (2-3 days),
responds to nutritional therapy more quickly and corre-
lates closely with nitrogen balance. It is therefore very
useful for monitoring nutritional support. 
The usefulness of transferrin in assessing protein
behaviour in these patients is made more difficult by
the frequent state of iron depletion and increased trans-
fusion requirements. 
• Subjective global assessment (SGA): This is a
simple tool used to identify patients with or at risk of
malnutrition at an early stage.11 It identifies patients
requiring nutritional intervention who would benefit
from intensive nutritional support.12,13
The SGA combines data on weight change, current
dietary intake compared to the patient’s usual intake,
gastrointestinal symptoms over the previous two weeks,
functional capacity and metabolic demands.14,15,16
In the patient-generated SGA (PG-SGA) (fig. 1), the
patients themselves are involved in the evaluation as
they complete the first part of the questionnaire, regar-
ding medical history, while the doctor completes the
rest of the assessment, regarding clinical symptoms.
This also reduces the amount of time needed to
complete the assessment. It is a questionnaire that can
be used in all medical environments, both with hospita-
lised patients and outpatients, either at appointments or
the patient’s home.17
Based on the result of the PG-SGA, the patient is
assigned to one of the three possible groups: A (well-
nourished), B (moderately malnourished or risk of
malnutrition) and C (severely malnourished). It has
been shown that use of this tool makes it possible to
discern the rate of patients at high risk of malnutrition
and to generate nutritional interventions that will, to a
large extent, help minimise complications due to
malnutrition, thereby having a major impact on the
quality of life of these patients.18
Detecting malnutrition is the first step towards esta-
blishing the different nutritional support measures and
therefore the nutritional assessment must be carried out
as soon as the disease is diagnosed and repeated to
monitor the nutritional status during the different
phases of the disease:
– When the patient is admitted to receive chemothe-
rapy and weekly throughout the hospital stay.
– If HSCT is required, from the start of HSCT and
throughout the hospital stay. With grade D, the
American Society for Parenteral and Enteral
Nutrition (ASPEN) recommends carrying out the
nutritional assessment prior to HSCT.19
– Following discharge from the hospital, follow-
up based on patient’s nutritional and functional
status. This follow-up should be continued until
the patient recovers an adequate nutritional
status. Some studies show that a large propor-
tion of patients do not recover their pre-treat-
ment weight until more than a year after
HSCT.20
Calculation of nutritional requirements 
To calculate nutritional requirements (NR), we
should take into account the patient’s clinical condi-
tion, type of treatment to be received (from interven-
tion with curative intent to palliative), presence or non-
Nutritional intervention in
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Fig. 1.—Patient-generated subjective global assessment.
PATIENT-GENERATED SUBJECTIVE GLOBAL ASESSMENT
Please complete the following form by giving the information requested or selecting the most appropriate option
Full name _________________________________________________ Age _________ years   Date    /   /
Current WEIGHT ____________ kg
Weight 3 months ago __________ kg
FOOD INTAKE compared to 1 month ago:
n I am eating more
n I am eating the same
n I am eating less
Type of food:
n normal diet
n little solid food
n only liquids
n only nutritional supplements
n very little
DAILY ACTIVITY over the past month:
n normal
n less than usual
n don’t feel like doing anything
n spend more than half the day in bed or sitting down
PROBLEMS EATING:
n Yes
n No
If the answer is Yes, indicate wich of the following
problems you have:
n no appetite
n nausea
n vomiting
n constipation
n diarrhoea
n smells bother me
n things have no taste
n funny taste
n feel full quickly
n problems swallowing
n dental problems
n pain. ¿Where __________________________
_____________________________________
n depression
n money problems
MANY THANKS. THE REMAINDER OF THIS FORM WILL BE COMPLETED BY YOUR DOCTOR
DISEASES: _____________________________________
_________________________________________________
_________________________________________________
ONCOLOGICAL TREATMENT: ________________
_________________________________________________
OTHER TREATMENTS: ________________________
_________________________________________________
ALBUMIN before
Oncological treatment: ___________ g/dl
PREALBUMIN after oncological treatment:
___________ mg/dl
PHYSICAL EXAM:
Fat deficit:
n Yes. Rating ______________________________
n No
Muscle deficit
n Yes. Rating ______________________________
n No
Oedema and/or ascites:
n Yes. Rating ______________________________
n No
Pressure sores:  n Yes    n No
Fever:  n Yes    n No
DECISION-MAKING SUPPORT PLAN IN PATIENT-GENERATED SUBJECTIVE GLOBAL ASSESSMENT
(modified from C. Gómez Candela and Spanish Nutrition and Cancer Advisory Group. Intervención Nutricional en el
Paciente Oncológico Adulto. Editorial Glosa. ISBN: 84-7429-176-3. Barcelona. 2003). Taking into account the SGA form,
consider or indicate the corresponding score for each of your patient’s clinical categories to obtain the final assessment:
CLINICAL CATEGORY A B C
Weight loss < 5% 5-10% > 10%
Food intake Normal mild-moderate decrease severe decrease
Impediments to oral intake
Mucositis No mild-moderate severe
Activity deficit No mild-moderate severe
Age ≤ 65 > 65 > 65
Pressure sores No No Yes
Fever/corticosteroids BMT No low/moderate high
Fat deficit NO mild/moderate severe
Muscle deficit NO mild/moderate severe
Oedema/ascites NO mild/moderate severe
Albumin (before Tx) > 3.5 3.0-3.5 < 3.0
Prealbumin (after Tx) > 18 15-18 < 15
FINAL ASSESSMENT    A: Well-nourished    B: Moderately malnourished or risk of malnutrition    C: Severely malnourished
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presence of malnutrition and its type, and functional
status.21,22
The Harris-Benedict equation will be used to calcu-
late calorie requirements with a stress factor of 1.3-1.5
according to the level of aggression to which the
patient will be subjected. On average, this calculation
tends to give 30-35 kcal/kg bodyweight/day. 
The presence of metabolic stress and disease
increase protein requirements to around 1.5-2 g
protein/kg ideal bodyweight/day.23
To optimise protein anabolism, it is important to
adapt non-protein energy intake to the amount of
protein administered. Patients with high metabolic
stress require a non-protein kcal/gram of nitrogen ratio
of around 100.24
A moderate glucose intake (never more than 5
g/kg/day) is recommended in oncological patients with
metabolic stress and insulin resistance to avoid the
onset of hyperglycaemia, lithogenesis and excess CO2
production.
Water and mineral requirements will vary based on the
patient’s weight and height and the underlying condi-
tion.21 Electrolyte, mineral and vitamin requirements will
be adapted to the needs of each patient and will be moni-
tored based on the treatment administered. Hypomagne-
saemia is common in patients being treated with platinum
derivatives (usual with rescue regimens in lymphoma) or
ciclosporin (usual immunosuppressant in allogenic trans-
plantation) as are reduced zinc levels in patients under-
going HSCT.23 Magnesium, potassium and phosphorus
levels should also be monitored during HSCT to correct
possible electrolyte imbalances.9
Nutritional considerations in 
onco-haematological patients 
To date, most published studies regarding nutrition
in onco-haematological patients have been conducted
in patients undergoing HSCT. 
Chemotherapy
Chemotherapy induces side effects of high meta-
bolic stress. Adverse reactions depend on the agent
used, the dose administered and individual susceptibi-
lity. However, tumour proliferative capacity and
chemotherapy sensitivity will also result in a greater
number of chemotherapy treatments and a greater toxic
effect, known as accumulated toxicity. Most chemot-
herapy agents, such as alkylating agents, anti-metabo-
lites, some vinca alkaloids, taxanes, anthracyclines or
anti-tumour antibiotics, affect those cells with the
fastest dividing capacity. That is why neoplastic cells
and digestive tract cells (cells in the mucosa lining the
digestive tract become inflamed due to damage caused
by the anti-cancer agents, which is known as muco-
sitis) will suffer from the effects of such agents most.
The intestinal mucosa suffers from oedema and blee-
ding due to ulceration resulting in malabsorption and
gastrointestinal motility alterations. Clinical symptoms
are primarily mucositis, nausea, vomiting and diarr-
hoea, compromising the patient’s nutritional status. 
Radiotherapy
Adverse reactions in patients undergoing radiothe-
rapy will depend on the area being irradiated and the
total dose administered. Therefore, patients under-
going total body irradiation (TBI) will suffer more
pronounced effects, primarily nausea and vomiting.25
Lesions are more intense when TBI is combined with
chemotherapy or immunosuppressive treatments admi-
nistered during the HSCT process. 
Haematopoietic stem cell transplantation (HSCT)
HSCT is an aggressive anti-neoplastic therapeutic
procedure for the digestive tract, consisting of the admi-
nistration of high doses of chemotherapy and/or radiothe-
rapy during the so-called conditioning phase followed by
the infusion of haematopoietic stem cells. This procedure
induces major gastrointestinal changes associated with
metabolic and nutritional status deficiencies. The main
symptoms that patients may experience are: long-term
loss of appetite, anorexia, nausea, vomiting, dysgeusia
and gastrointestinal motility disorders in the form of
persistent diarrhoea. Serious digestive complications
such as paralytic ileus, neutropenic colitis or typhlitis
may sometimes occur. Moreover, toxicity in intestinal
cells can lead to diarrhoea and malabsorption, making it
hard to absorb nutrients. The presence of acute or chronic
graft-versus-host disease (GVHD) may prolong the dura-
tion of gastrointestinal symptoms.
The presence and severity of HSCT complications
varies according to the type of transplantation and condi-
tioning regimen, as is the case in patients undergoing
allogenic unrelated donor transplantation.20 The main
causes of gastrointestinal alterations during HSCT are the
direct cytotoxic effect of chemotherapy on the digestive
tract cells and the prolonged myelosuppressive effect.
The added presence of potentially serious complications
such as acute or chronic graft-versus-host disease
(GVHD) or sinusoidal obstruction syndrome (SOS,
previously called hepatic veno-occlusive disease) will
determine the patient’s clinical outcome. 
Nutritional support in 
onco-haematological patients
Objectives
The objectives of nutritional support for onco-
haematological patients are no different from the
general objectives for oncological patients,26 namely:
Nutritional intervention in
onco-hematological patients
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• To prevent malnutrition and related complica-
tions. 
• To improve nutritional status in previously
malnourished patients. 
• To improve tolerance of onco-haematological
treatment and its effectiveness by allowing such
treatment to be given at the established time with
the necessary dose and duration. 
• To improve perception of quality of life.
Indications for nutritional support
Specialised nutritional support (SNS) should be
indicated in:
a) Patients with malnutrition.
b) Patients whose oral intake provides less than
70% of their nutritional requirements for 3 conse-
cutive days. 
c) Patients with complications that compromise the
patient’s nutritional status.
Both the American Society for Parenteral and
Enteral Nutrition (ASPEN)19 and the European Society
(ESPEN)27 agree that there is no indication for routi-
nely starting NS in oncological patients who are to
undergo radiotherapy and/or chemotherapy.
Nutritional support protocol in 
onco-haematological patients
In order to apply the nutritional intervention protocol
to patients with haematological neoplasms, we have
taken the protocol designed by the Grupo Multidisci-
plinar de Nutrición y Cáncer (Multidisciplinary Nutri-
tion and Cancer Group) of the Sociedad Española de
Nutrición Básica y Aplicada (Spanish Society for Basic
and Applied Nutrition)6 as our starting point. This paper
defines an algorithm that can help us make decisions
regarding the nutritional support of cancer patients. This
algorithm takes into account the following variables
when establishing the most appropriate nutritional
support for each type of patient:
a) The first variable considered is therapeutic intent:
curative or with palliative intent. 
a) The following is advised in patients with
advanced disease receiving palliative care: 
a) 1. To give priority to the patient’s own wishes
regarding whether or not to improve his/her
level of intake and/or nutritional status.
a) 2. To discuss and agree on any diet objectives
with the patient and to integrate these objec-
tives into the patient’s therapeutic plan so that
the two are compatible.
a) 3. To control the most prevalent symptoms
affecting nutritional status. 
a) 4. To determine which patients have a life prog-
nosis of less than 4 weeks. In this case, the
fundamental objective of nutritional interven-
tion is to offer the maximum possible comfort,
without trying to modify the actual nutritional
status.
a) 5. To obtain the necessary assistance from
psychologists and social workers to provide
support to both the patient and his/her family.
a) There are two aspects in palliative care patients
that require special attention: the level of glyca-
emic control and dehydration.57
b) The second variable considered is the patient’s
nutritional status via the Patient-Generated
Subjective Global Assessment, which allows us
to classify the patient as either well-nourished,
moderately malnourished or severely malnou-
rished. 
c) The last variable to consider is the nutritional risk
of the anti-neoplastic therapy (fig. 2). Patients
who are to undergo HSCT require special consi-
deration (fig. 3). 
Types of nutritional support
The nutritional treatment plan includes oral diet,
nutritional supplementation and artificial nutrition
when nutritional needs cannot be met any other way. 
Oral diet 
Various symptoms will determine oral diet needs in
onco-haematological patients: anorexia, dysgeusia,
nausea, vomiting, xerostomia, mucositis, etc. Dietary
recommendations will be aimed at increasing the
energy and protein intake of the patient’s diet. These
recommendations will be adapted according to the
patient’s symptoms.23
Opportunistic infections are still a major cause of
morbidity and mortality in immunocompromised
patients. The use of low-bacteria diets may reduce the
incidence of infections by decreasing exposure to
bacterial agents during periods of neutropenia. Some
studies have examined the role of diet and infectious
risk in combination with other interventions. However,
it is hard to make comparisons due to the large variabi-
lity in dietary restrictions. It is necessary to conduct
more studies in this area.19,28 Until then, the implemen-
tation of dietary restrictions when purchasing, storing,
handling and preparing certain foods during periods of
neutropenia is indispensable. Basic recommendations
for a low-bacteria diet include:
a) Using food hygiene and handling guidelines to
prevent contamination.
b) Avoiding the consumption of raw meat, fish or
eggs.
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c) Using pasteurised, tinned and cooked food
whenever possible.
d) Avoiding raw vegetables.
Mucositis is a common complication of chemothe-
rapy, especially in patients undergoing HSCT.
According to data from the European Mucositis
Advisory Group,29 oral mucositis is classed as severe
(grades 3 and 4) in 46% of patients during HSCT
conditioning.
With severe mucositis, the presence of ulcers and
other extremely painful lesions almost completely
compromises the patient’s oral intake, notably increa-
sing the risk of malnutrition, dehydration and infection.
The nutritional approach for mucositis must be aimed
at meeting the nutritional needs of the patient by modif-
ying the texture of the diet. Sometimes simply adapting
the diet is not enough and the addition of nutritional
supplementation is required. 
Nutritional supplementation
Nutritional supplementation is an effective way to
increase intake of macro- and micronutrients in onco-
haematological patients who cannot meet their nutri-
tional needs with oral diets. Oral supplementation has
proven effective at maintaining or improving the nutri-
tional status of hospitalised onco-haematological
patients, using both commercial supplements and
home-made supplements using conventional foods.30
Enteral nutrition
The use of enteral nutrition (EN) is indicated in
malnourished patients who have a functioning
gastrointestinal tract but are unable to meet their nutri-
tional requirements by oral intake alone (ASPEN,
grade C). Enteral nutrition has shown numerous advan-
tages over parenteral nutrition in onco-haematological
patients, including a reduced incidence of diarrhoea,
less hyperglycaemia,31 less risk of severe GVHD and
infections.32
Many groups have studied the use of enteral nutri-
tion as an alternative to parenteral nutrition in patients
undergoing HSCT. Enteral nutrition generally offers
numerous advantages over parenteral nutrition: it is
more physiological, it has a lower cost and complica-
tion rate, more efficient use of nutrients, preservation
of functional integrity, immunological benefits and a
lower rate of bacterial translocation.32,33
Nutritional intervention in
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Fig. 2.—Nutritional assessment and support in onco-haematological patients.
ONCO-HAEMATOLOGICAL DIAGNOSIS
NUTRITIONAL RISK ASSOCIATED
WITH ANTI-NEOPLASTIC THERAPY
TERMINAL PATIENT
PALLIATIVE CARE
LOW RISK
WELL-NOURISHED
YES NO
SEVERE MODERATE
ONS
If intake < 70%
reqs 3 consecutive
days
MUCOSITIS
HIGH-MODERATE RISK
NUTRITIONAL STATUS
ASSESSMENT
EN ± PN
ONS ± EN
EN
MILD-MODERATE
MALNUTRITION
SEVERE
MALNUTRITION
DIETARY RECOMM.
NUTRITIONAL SCREENING
NO NUTRITIONAL
RISK
NUTRITIONAL
RISK
NUTRITIONAL STATUS
ASSESSMENT
DIETARY RECOMM.
NO NUTRITIONAL SUPPORT
REPEAT SCREENING IF
TREATMENT ACTIVE
Low-risk therapy: chemotherapy generally done as outpatient.
High-moderate risk therapy:
– Acute myeloid leukaemia induction/consolidation regimens with
intermediate-high doses of cytarabine.
– High-risk acute lymphoblastic leukaemia induction regimens.
– Rescue regimens for lymphoma with gastrointestinal toxicity.
– Primary cerebral lymphoma treatment regimens.
ONS: Oral Nutritional Supplementation
EN: Enteral Nutrition
PTN: Parenteral Nutrition
NRQ: Nutritional Requirements
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However, there is a lot of controversy and great
variability in its use due to the fact that its use is limited
by gastrointestinal dysfunction associated with the
toxicity of anti-neoplastic treatments, thrombocyto-
penia and neutropenia. Generally, HSCT patients are
not good candidates for administration of total enteral
nutrition due to nausea, vomiting, oro-oesophageal
mucositis and poor tolerance of nasogastric tubes.28,34
Some published guidelines on enteral nutrition have
demonstrated the need to supplement between 14-
100% of cases with parenteral nutrition as a result of it
being impossible to meet nutritional requirements by
enteral route alone.35,36,37 Early EN is associated with
better tolerance. Some studies32,37 have shown that
insertion of the NG tube during the week of haemato-
poietic stem cell infusion improves enteral nutrition
tolerance. During conditioning treatment, the risk of
the NG tube being dislodged due to nausea and vomi-
ting is high. 
With regard to the route of administration, both
nasogastric and gastrostomy tubes have been used. In
some cases, the tube has been inserted prior to the
transplant to avoid the risk associated with inserting the
tube when mucositis is already present due to the fria-
bility of the tissue. Nasogastric tube placement is
considered safe provided that mucositis is grade 2 or
less. A minimum count of 0.5-1 x 109/l neutrophils and
10-20 x 109/l platelets is also required.33,34 Nevertheless,
it is recommended that the haematologist in charge be
consulted to evaluate the risk of bleeding.
The use of low-osmolality, polymeric enteral
formulas as a continuous infusion are generally well
tolerated. Some authors32 recommend gradually increa-
sing the infusion rate as tolerated by the patient or
changing to a high-energy formula until the patient’s
nutritional needs are met in about one week. Regarding
the use of specific nutrients, ESPEN gives a grade C
recommendation with regard to the use of formulas
rich in omega 3, alleging that there are no conclusive
data to routinely support this recommendation in
cancer patients.27
ESPEN does not recommend the use of routine
enteral nutrition in HSCT patients (grade C), indicating
that parenteral nutrition would be preferable in patients
with an increased risk of haemorrhage or infection and in
immunocompromised or thrombocytopenic patients.27
Despite this, there are authors who support enteral
nutrition being considered a valid option in this type of
patient, especially when scheduled prior to the onset of
mucositis.32,33,38 Lipkin et al. reviewed the characteris-
tics of HSCT patients who are candidates for enteral
nutrition (table II).
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Fig. 3.—Nutritional support algorithm in patients who are candidates for haematopoietic stem cell transplantation.
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Parenteral nutrition
The route of administration, whether central or perip-
heral, will depend on the planned duration of nutritional
support. However, like non-oncological patients, it is
common for onco-haematological patients, especially if
undergoing HSCT, to be fitted with a long-term central
line for chemotherapy (generally a Hickman line),
which we can use for the administration of parenteral
nutrition.
With regard to indications for TPN in HSCT
patients, the European Guidelines on Enteral and
Parenteral Nutrition (ESPEN) specifically recom-
mend (Grade B) that it should be reserved for patients
with ileus, severe mucositis and intractable vomiting
and should not be routinely administered. To
conclude, the use of TPN is proposed in those patients
meeting criteria for malnutrition or a major risk of
malnutrition and in patients in whom digestive toxi-
city is expected to continue being a limiting factor for
oral or enteral intake.28 Gastrointestinal toxicity is
therefore the limiting factor for oral intake and the
main indication for parenteral nutrition. Such toxicity
is variable depending on the agent used. However,
toxicity-dependent indications for parenteral nutri-
tion may be modified in the future with the develop-
ment of effective gastro-protective therapies. There is
already a large number of drugs being studied for this
purpose, including interleukin 11, sucralfate, amifos-
tine and keratinocyte growth factor.
The best time to start TPN is unclear.38 At some
hospitals, this type of treatment is part of routine
clinical care for HSCT and its start is determined by a
set schedule. At La Paz University Hospital, parenteral
nutritional support is started according to protocol on
day +2 of HSCT, unless the patient is already showing
signs of limited oral intake or elevated digestive toxi-
city prior to HSCT, in which case parenteral nutrition
will be started earlier.39 At Hospital Vall d’Hebron and
Instituto Catalán de Oncología, TPN is only started if
oral and/or enteral feeding fails.
In terms of specific nutrients in the TPN formula of
HSCT patients, glutamine and different types of lipid
emulsions have been studied.40 The provision of micro-
and macronutrients has been specifically covered in the
calculation of requirements section, although it is
worth highlighting that HSCT imposes high levels of
stress that will have to be considered when calculating
requirements. 
European Guidelines recommend gradually discon-
tinuing TPN when the patient can meet 50% of his/her
needs by oral intake (grade C).38
Specific nutrients
Glutamine
Glutamine is a non-essential amino acid that may be
conditionally essential in patients in hypercatabolic
states. It helps maintain the integrity of the intestinal
mucosa by reducing intestinal atrophy and can improve
weakened immune function in onco-haematological
patients. 
Glutamine plays an important role in nitrogen trans-
port and as a precursor for nucleotide synthesis.
Although several studies44,46,47 have evaluated the effect
of enteral or parenteral administration of glutamine on
gastrointestinal toxicity, none have shown a clear
preventative or therapeutic effect on intestinal muco-
sitis.
On the other hand, prospective studies suggest posi-
tive effects of glutamine on length of hospital stay,
nitrogen balance, infectious complications, early
HSCT-related mortality and incidence of GVHD.41,42,43
In the literature, we found different studies, syste-
matic reviews and meta-analyses with contradictory
conclusions and recommendations. The latest review
of Cochrane44 shows no clinically beneficial effects in
the use of parenteral glutamine in HSCT patients, but
both the ASPEN19 and ESPEN guidelines38 conclude
that parenteral glutamine has a beneficial effect in
Nutritional intervention in
onco-hematological patients
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Table II
Characteristics of patients who are candidates for enteral nutrition during haemotopoietic stem cell transplantation
Conditioning regimen • Reduced intensity.
• Myeloablative with low gastrointestinal toxicity profile.
Type of transplant HLA-matched related donor.
Critical patient Trophic enteral nutrition or total enteral nutrition if the digestive tract is stillfunctional. 
Problems with parenteral-to-oral transition after resolving toxicity from
Prolonged recovery chemotherapy.
Patient malnourished or with high risk of malnutrition.
Pre-established access.
Access devices Limited central venous access devices.
Patient’s consent to insert tube.
Adapted from Lipkin A et al., 2005.
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patients undergoing HSCT. The immense variability of
the studies used and the different interpretations of
such studies make it hard to reach definitive conclu-
sions. Some studies show benefits in terms of infec-
tions,42,45 length of hospital stay41,45,46 or short-term
mortality42 while others show contradictory results or
insignificant differences.47,48
ASPEN has recently published an exhaustive review
of the use of glutamine in parenteral nutrition49 and
concludes that there is a trend towards fewer positive
blood cultures with the use of parenteral glutamine in
HSCT patients receiving TPN. However, it warns that
the potential beneficial effect of glutamine supplemen-
tation remains unclear since there is only a reduced
length of hospital stay in studies combining autologous
and allogeneic transplants while no advantages have
been shown when given post-transplant to those solely
undergoing autologous transplantation. Finally, it
concludes that glutamine supplementation should be
further investigated in the areas of timing, dosing and
cost-benefit analysis. In the review conducted by
Martin-Salces et al., the recommended dose is up to
0.5-0.7 g/kg/day22 in HSCT patients. 
Therefore, well-designed studies are needed to
assess the potential benefits of glutamine in HSCT
patients that evaluate the best time to start glutamine
supplementation (pre-transplant vs. post-transplant),
route of administration (oral/enteral vs. parenteral),
duration of supplementation and medium to long-term
effects (relapses, GVHD, SOS). The cost-benefit
analysis of glutamine supplementation should also be
evaluated.
Probiotics
The use of probiotics to treat diarrhoea in onco-
haematological patients is controversial, despite theo-
retical potential benefits. At present, their use in such
patients is not advised due to their immunodeficiency,
risk of colonisation and bacteraemia.33
Lipid emulsions
Soybean oil-derived lipid emulsions are rich in
polyunsaturated fatty acids and are more susceptible to
oxidation, which could potentially affect immune
system function. The effect on oxidative stress and
plasma lipid profile in HSCT patients of several lipid
emulsions with a higher or lower long-chain triglyce-
ride (LCT) content has been compared with oleic acid-
enriched emulsions.50 Oleic acid-enriched emulsions
have shown a smaller increase in oxidative stress as a
result of decreased lipid peroxidation and lower plasma
lipid profile alterations. They should therefore be
considered in TPN for HSCT patients. 
The effect of the different lipid emulsions on evolu-
tionary parameters in HSCT patients (time to engraft-
ment, hospital stay, infections, etc.) has yet to be inves-
tigated.
Nutritional support in complications of HSCT
Graft-versus-host disease (GVHD)
GVHD is a complication of allogenic HSCT that
occurs when immunocompetent cells in the graft detect
antigens in the recipient’s cells. It can be acute or
chronic. In its acute form, it primarily affects the skin,
liver and gastrointestinal tract. Intestinal GVHD is
characterised fundamentally by varying degrees of
mucositis associated with diarrhoea with or without
nausea, vomiting, abdominal pain and occasionally
ileus. It results from the destruction of the intestinal
crypts, with gastrointestinal toxicity developing,
ranging from profuse secretory diarrhoea with conse-
quent severe faecal nitrogen loss to mucosal ulcers
with possible perforations and need for emergency
surgical treatment. Skin involvement leads to erythro-
derma, which usually appears on the cheeks, trunk,
soles of the feet, palms and the retroauricular region.
When the liver is affected, severe cholestasis appears
as a result of the destruction of small bile ducts. 
Chronic GVHD consists of the onset of signs and
symptoms after post-transplant day 100, fundamen-
tally recurrent infections, associated immune diseases
and cutaneous-mucosal, eye, gastrointestinal, hepatic
and pulmonary conditions, among others. Gastrointes-
tinal involvement affects 16% to 25% of patients, with
signs and symptoms appearing secondary to oesopha-
geal motility disorders, dysphagia and odynophagia,
nausea, vomiting, abdominal pain and diarrhoea, resul-
ting in weight loss. Treatment consists of steroids and
immunosuppressants together with support, depending
on the organ affected. 
Nutritional support of severe acute GVHD is still
under debate. Some studies suggest that limited oral
intake may be associated with an increased risk of severe
acute GVHD following HSCT.51 The diarrhoea that
occurs during GVHD is multifactorial and includes
secretory dysfunction, although osmotic factors and
rapid passage are also involved. Classically nothing by
mouth and TPN were recommended to reduce stool
volume and improve pain in patients suffering from
post-prandial pain. However, this approach results in
intestinal mucosal atrophy and dysfunction, potentially
leading to bacterial translocation and difficulty restar-
ting oral feeding. Various studies have shown that
enteral nutrition is safe using hypo-osmolar diets,
without exacerbating digestive symptoms of GVHD.52
Nevertheless, it is not uncommon for patients with very
high stool volume to need intravenous nutrient replace-
ment due to the high intestinal losses and the fact that it is
impossible to meet nutritional requirements via the
gastrointestinal tract. It should be considered that certain
risks may be associated with TPN, such as hyperglyca-
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emia, hepatic impairment and an increased risk of TPN-
associated infection.23,31 Therefore, the most suitable
nutritional approach probably includes maintaining the
digestive tract with a low-residue and low-lactose oral
diet or a hypo-osmolar enteral diet, assessing the need
for complementary TPN on an individual basis. 
However, when the state of malnutrition is main-
tained for long periods of time, as is the case in HSCT
patients, the use of nutritional support exclusively in
the form of TPN is associated with atrophy of the intes-
tinal mucosal villi and their immune function, promo-
ting bacterial translocation and endotoxin absorption,
both of which are involved in the development and
maintenance of sepsis and multiple organ failure. 
As a result, assessment of the nutritional status and
optimal support are essential for maintaining the nutri-
tional status of the patient during HSCT.
Sinusoidal obstruction syndrome (SOS)
Sinusoidal obstruction syndrome, formerly known
as hepatic veno-occlusive disease, is a serious compli-
cation of HSCT in which the sinusoidal epithelial cells
are damaged during the conditioning regimen.53 Morta-
lity may be up to 25% of cases.54 The damaged epithe-
lial cells may slough, causing congestion and obstruc-
tion of blood flow through the hepatic sinusoid. SOS is
characterised by hepatomegaly, fluid retention, ascites
and jaundice.
Patients with SOS often require parenteral nutri-
tional support. The parenteral nutrition formula will be
determined by the need to restrict fluids and specifi-
cally sodium. Furthermore, given the extreme liver
impairment and cholestasis associated with the condi-
tion, manganese should be restricted to avoid accumu-
lation of this element and associated neurotoxicity.
Lipid emulsions should be adjusted due to hepatopathy
and a high frequency of hypertriglyceridemia.
Some authors suggest that glutamine infusion may
act as a liver protector, reducing the oxidative stress
associated with conditioning treatments, and may
therefore prevent the onset of SOS.55
Conclusions
The objective of this paper is to establish a protocol
for the nutritional treatment of onco-haematological
patients with the hope that this may result in an
improved efficacy and tolerance of treatments and an
improved quality of life for patients during oncological
treatment.56,57
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